SELLAS Life Sciences Group Inc (SLS) News

I'm not giving you the valuable research that I did. One thing for sure is you know little about clinical trials.

Can the BAT change during a trial? Or must these CR2 patients in that arm just live (or rather die) with the old treatments from 2019? Would that be ethical? Would that be a test of BAT if it did?

The Regal trial protocol was written in 2019… the five choices for BAT haven’t changed, yes ven/aza combo is in BAT… but lip services from leading clinicians in 2023 re: the same treatment options since ven/aza available since 2017-18… puhlease. Why don’t you give me some FACTS like I’m doing for you? Explain your BAT 13 mOS with data!

Correct, my estimate. Those VIALE-A trials on CR1 patients were 3+ years ago. Other trials on CR2 patients were also years ago. The field has moved on since then and knows how to treat patients on ven/aza with additional inhibitors depending on the karyotypes presented. MRD negative status is also a huge helper in addition to patient age.

The doctors on the conference call last January were just giving lip service. Again, are you going to be able to sue them for saying "CR2 patients have a low 5-7 months expected survival"? If BAT MOS was 6 months, you would already have your 60 events. My last estimate has BAT 13 MOS vs GPS 21 MOS (0.619). It's very tight and the fact that Abbvie and Roche are seeing no degradation in stock price (and SLS seeing absolute nothing in stock price) indicates that it is not going to be a white Christmas.

Your estimate!! So you see BAT living 13-14 mos?? Double of what the Drs conducting the trial, and the majority of CR2 trials produced? IA needs an HR on .52, and i bet they are close to that. P2 was 21 vs 5.5 mos and that was with a 12 injection schedule, not the 15 in Regal.

Correct. To pass muster at Final Analysis, they need to be 0.636. So at the last meeting, it is very tight. My estimates show it to be at 0.619.

So in June, at 0.619, you would not get a "halt for futility" or any "futility concerns". You would only get that if the HR number was above 0.636 and you still may not get a "futility halt" if the number was just slightly above 0.636 (say 0.643) at the time they looked at the data. You need to understand that the CEO (and company) is grifting investors.

Let's put it another way, when the trial fails, what "evidence" are you going to use to sue Stergiou and/or the company for lying about the trial? You won't have any because they have covered their bases.

Is that what you took from the IDMC’s last Regal update of “NO CONCERNS REGARDING SAFETY OR FUTILITY”?

REGAL has failed means that the upcoming readout will be receiving a failing grade. They can't report until the 60th event, but at this point, it is obvious that this trial is DOA. Oncology is hard.

If Regal “has failed” it would be a material event and the company must inform the public with 3 trading days! You talk about “pumpers” and yet you state the trial has failed w/o a shred of evidence! That called FUD, but you already knew that, right?

Well, I used to think Sellas was going to be a stock to play. I used to think that it was going to have some decent volatility heading into September that would have nice to swing trade. But now, I will recognize that this stock is a sham. If you just go read the posts on other boards (like Stocktwits), it is like a desperation pump show. Ignore the posters over there like @GPS_vs_SOC and a few others that post all the time. Instead, watch the posters that do post with some regularity continually saying "they bought more shares" or "this is going to rocket soon" or etc, etc, etc...

In all likelihood, GPS REGAL trial has failed. Oncology is a tough business and it is even tough when the CEO is retarded.

SLS under $2

Is it going to be a sh_t show for Sellas? Or a REG SHO extravagammasqueeze?

SLS under $2

SLS under $2

https://duediligencegenie.com/wp-content/uploads/2024/05/Sellas-Life-Sciences.pdf This should be sticky posted.

The longer this goes, it is gonna POP… BP gotta know what SLS has, 2,assets that are extending OS 3 to 5X.

https://www.barchart.com/stocks/quotes/SLS/opinion

dilution turd

Moneymaker here folks$$$$$

VERY OBSERVANT, THANK YOU FOR THE ANALOGY! TOMORROW MIGHT MAKE A DIFFERENCE****WE SHALL SEE

Lol, oh there are still a stash of those, in the 20’s! $$$$$!!

You should have taken CVNA which go to da moon
Now back to getting richer

Huge move up could happen anytime, lottery play could go to da moon! $$$$$

With positive REGAL results this will eventually explode

According to the charters, which I am not, 9 million volume traded so far today - largest volume day in 3 years - 6 of the 9 million sold short

SLS under $2

SURPRISED SLS IS NOT MOVING**** WAS AN EXCELLENT NEWS***** HOW ARE U *******

YOU ARE NOT AS FREQUENT AS BEFORE , YOU MUST BE SOMEWHERE ELSE***SHARE THE KNOWLEDGE

Let er rip

1.27 SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level $SLS https://t.co/bQBsEQo7jc— Health Stocks News (@health_stocks) May 1, 2024

Somebody shorted the sh.. out of this today, pretty risky at this point, but whatever….

Yahoo finance add sls and review of the conversations tab.

you have a link ?

On yahoo they are talking 4 min.

Agree, might see 1.70’s again, worth the risk with a stop limit on shares purchased at 1$ or more

ok thanks

I believe it’s gonna before EOM… pr stated idmc scheduled ‘by’ EOM…

yup think next month data phase3 end april ... should see 1.50s before data

Maybe another pop to 1.60

SLS 10Q due 3/22

SLS under $2

Hit an run with this one

No way, lotto play here. This is nothing but risk

Let’s go $$$$$ reeling $$$$$$

Junk

SLS new 52 week low

And Dilution.

Merry Christmas $$$$$

Doubt it, insiders just sold shares!

Rumor mill over on Stocktwits is that STELLAS is about to receive Orphan Drug status for their T-cell lymphoma treatment. No PR out yet but,.... Dated today,...

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=977523

Climbing back up